Dr Reddy's Laboratories Ltd
F:RDDA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
Dr Reddy's Laboratories Ltd
F:RDDA
|
IN |
|
PSP Swiss Property AG
LSE:0QO8
|
CH |
|
Shriram Finance Ltd
BSE:511218
|
IN |
|
G
|
GEA Group AG
LSE:0MPJ
|
DE |
|
N
|
Neuraxis Inc
AMEX:NRXS
|
US |
|
HDFC Bank Ltd
NSE:HDFCBANK
|
IN |
Dr Reddy's Laboratories Ltd
Dr Reddy's Laboratories makes and sells generic medicines, branded prescription drugs, and active pharmaceutical ingredients, or the chemical ingredients used to make medicines. It also develops some specialty products and biosimilars for complex diseases. The company serves patients, doctors, pharmacies, hospitals, and health systems in India and in overseas markets such as the United States, Europe, and other regulated regions. Most of its money comes from selling finished medicines and pharmaceutical ingredients. In generics, Dr Reddy's earns revenue by offering lower-cost versions of off-patent drugs after patents expire. In specialty and biosimilar products, it sells harder-to-make treatments that need more development, regulatory work, and manufacturing skill. It also supplies ingredients to other drug makers, which makes it part of the pharmaceutical supply chain as both a drug seller and a manufacturer for other companies. What makes the business model different is its mix of domestic branded medicines, export-led generic drugs, and ingredient manufacturing. That gives it several ways to reach customers and reduces reliance on one product type or one market. The company competes in a heavily regulated industry, so approvals, quality control, and manufacturing standards are central to how it grows and protects its business.
Dr Reddy's Laboratories makes and sells generic medicines, branded prescription drugs, and active pharmaceutical ingredients, or the chemical ingredients used to make medicines. It also develops some specialty products and biosimilars for complex diseases. The company serves patients, doctors, pharmacies, hospitals, and health systems in India and in overseas markets such as the United States, Europe, and other regulated regions.
Most of its money comes from selling finished medicines and pharmaceutical ingredients. In generics, Dr Reddy's earns revenue by offering lower-cost versions of off-patent drugs after patents expire. In specialty and biosimilar products, it sells harder-to-make treatments that need more development, regulatory work, and manufacturing skill. It also supplies ingredients to other drug makers, which makes it part of the pharmaceutical supply chain as both a drug seller and a manufacturer for other companies.
What makes the business model different is its mix of domestic branded medicines, export-led generic drugs, and ingredient manufacturing. That gives it several ways to reach customers and reduces reliance on one product type or one market. The company competes in a heavily regulated industry, so approvals, quality control, and manufacturing standards are central to how it grows and protects its business.
Revenue: Dr. Reddy’s said FY '26 was its highest-ever annual revenue year, with the base business continuing to grow double digits even after a major one-time hit from lenalidomide.
Lenalidomide hit: Q4 was dragged by a INR 453 crores shelf-stock adjustment tied to lenalidomide, which management said came from customer-side planning issues and was not part of any arrangement.
Margin outlook: Gross margin came in at 48% in Q4 because of product mix and pricing pressure, but management said it expects margins to move back above 50% in FY '27.
Pipeline progress: The company won Canada approval for semaglutide injection, got India approval for oral semaglutide, and said the abatacept IV filing was accepted by the U.S. FDA for review.
Growth drivers: Management expects North America to return to double-digit growth ex-lenalidomide next year, while semaglutide, biosimilars, consumer health and new launches should support the next leg of growth.
Spending plan: SG&A is expected to stay around FY '26 levels in nominal terms, while R&D spend should fall to 7% to 8% of sales next year as abatacept trial spending rolls off.
Capital allocation: The board recommended a dividend of INR 8 per share, and the company ended the year with a net cash surplus of INR 3,271 crores.
